|
|
Article: The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
- Article from:
- PR Newswire
- Article date:
- October 13, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Researchers aim to advance treatment options for people living with Alpha-1 Antitrypsin deficiency
RESEARCH TRIANGLE PARK, N.C. and MIAMI, Oct. 13 /PRNewswire-FirstCall/ -- The Alpha-1 Foundation announced today that it has awarded two research grants to study how genetic variations in the alpha-1 antitrypsin (AAT) gene contribute to lung and liver damage in people with AAT deficiency. The inherited condition causes emphysema and liver disease. The research will also investigate whether AAT infusion therapy -- known as augmentation therapy -- minimizes liver damage among individuals with AAT deficiency.
The grants were awarded to Noel G. McElvaney, M.D., ...